Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer

Histopathology

Volumn 44, Issue 4, 2004, Pages 332-338

  Varga, Z ^a   Zhao, J ^a   Ohlschlegel C ^b   Odermatt, B ^a   Heitz, P U ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Breast cancer; FISH; HER 2 neu; Special type; Unfavourable prognosis

Indexed keywords

GLYCOGEN; LIPID;

ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2;

EID: 1842855321     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01843.x     Document Type: Article

References (26)

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998: 11; 155-168.
2. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur. J. Cancer 2001: 37; S3-S10.
3. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn. Mol. Pathol. 2001: 10; 139-152.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N. Engl J. Med. 2001: 344; 783-792.
5. Kuter I, Breast cancer. Oncologist 2001: 6; 338-346.
6. Rosen PP. Apocrine and secretory carcinoma. In Swan K ed. Rosen's breast pathology, 1st edn. Philadelphia: Lippincott-Raven Publishers, 1997; 421-430, 441-448.
7. Sloane JP. Secretory, lipid-rich and glycogen-rich carcinoma. In Lakhani SR ed. Biopsy pathology of the breast. 2nd edn. London: Arnold Publishers. 2001: 189-190, 194-195.
8. Tavassoli FA. Apocrine and secretory carcinoma. In Medina MP and Greenfield S eds Pathology of the breast, 2nd edn. Stamford: Appleton & Lange. 1999: 504-515, 522-527.
9. Bundred NJ, Stewart HJ, Shaw DA, Forrest AP, Miller WR. Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer. Eur. J. Cancer 1990: 26; 1145-1147.
10. Pagani A, Sapino A, Eusebi V, Bergnolo P, Bussolati G. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows. Arch. 1994: 425; 459-465.
11. Frolik D, Caduff R, Varga Z. Pleomorphic lobular carcinoma of the breast: a comparison of its cell kinetics, expression of oncogenes and tumour suppressor genes as opposed to invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 2001: 39; 503-513.
12. Pauletti G, Dandekar S, Rong HM et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 2000: 18; 3651-3664.
13. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST. Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J. Clin. Pathol. 2000: 53; 374-381.
14. Barlett JMS, Going JJ, Mallon EA et al. Evaluating Her2 amplification and overexpression in breast cancer. J. Pathol. 2001: 195; 422-428.
15. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of Her2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 2002: 20; 3095-4005.
16. Varga Z, Caduff R. Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments. Breast Cancer. Res. Treat. 1999: 57; 215-219.
17. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am. J. Surg. Pathol. 2000: 2; 1650-1656.
18. Middleton LP, Tressera F, Sobel ME et al. Infiltrating micropapillary carcinoma of the breast. Mod. Pathol. 1999: 12; 499-504.
19. Paterakos M, Watkin WG, Edgerton SM, Moore IIDH, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum. Pathol. 1999: 30; 1459-1463.
20. Nassar H, Wallis T, Andea A, Jyotirmoy D, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod. Pathol. 2001: 14; 836-841.
21. Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum. Pathol. 2001: 32; 583-589.
22. Thor AD, Eng C, Devries S et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum. Pathol. 2002: 33; 628-631.
23. Luna-More S, de los Santos F, Breton JJ, Canadas MA. Estrogen and progesterone receptors, c-erB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Pathol. Res. Pract. 1996: 192; 27-32.
24. Varga Z, Robl C, Spycher M, Burger D, Caduff R. Metaplastic lipid-rich carcinoma of the breast. Pathol. Intern. 1998: 48; 912-916.
25. Matsuo K, Fukutomi T, Hasegawa T, Akashi-Tanaka S, Nanasawa T, Tsuda H. Histological and immunohistochemical analysis of apocrine breast carcinomas. Breast Cancer 2002: 9; 43-49.
26. Gancberg D, Lespagnard L, Rouas G et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Am. J. Clin. Pathol. 2000: 113; 675-682.